Can CYP2C19 help with Wechseljahre?

CYP2C19 is a drug-metabolizing enzyme, not a direct biomarker for menopause. During menopause, medications such as antidepressants (e.g., citalopram, escitalopram) or hormone replacement therapy (HRT) may be prescribed, and their efficacy and side effects can be influenced by CYP2C19 variants. However, evidence for a direct benefit of CYP2C19 testing in menopause is weak – no large studies show that genotyping improves menopausal symptoms. Some pharmacogenetic guidelines (e.g., CPIC) recommend dose adjustments for certain antidepressants, but not specifically for menopausal complaints. Additionally, data on CYP2C19 and endogenous hormones (estrogen, progesterone) is limited and conflicting. A genetic test can at best serve as supplementary information for personalized medication, not as a diagnostic or prognostic tool for menopause itself. Caution: no self-medication without medical supervision. Evidence: mechanistic/pharmacogenetic, but not menopause-specific.